Effect of Supplementation with Lutein, Zeaxanthin, and Omega-3 Fatty Acids on Macular Pigment and Visual Function in Young Adults with Long-Term Use of Digital Devices: Study Protocol for a Randomized Double-Blind Placebo-Controlled Study
Lina Wang,Mei Ma,Yong Li,Cheng Pei,Jianming Wang,Juan Li,Linjuan Yang,Qianying Liu,Li Tang,Yang Hao,Huili Jiang,Jiaxuan Fu,Yuyao Xiao,Yahui Wang,Meng Cui,Tong Su,Jiaqi Bai,Hao Tang,Yue Wang,Hongying Shan,Hong Jiang,Chaoming Deng,Liyun Kong,Zhaozhao Hui,Le Ma
DOI: https://doi.org/10.3389/fnut.2024.1422468
IF: 5
2024-01-01
Frontiers in Nutrition
Abstract:BackgroundGrowing evidence emphasizes the importance of xanthophyll carotenoids and omega-3 fatty acids in eye health. However, the beneficial effects of such supplementation have not been thoroughly discussed among adults with high screen exposure. Current trial evidence on lutein bioavailability is contradictory, and the interactions of dietary intervention with host-related factors remain elusive. This study aims to investigate the comparative effectiveness of supplementation with macular xanthophylls and omega-3 fatty acids on macular pigment optical density (MPOD) and visual function, access the bioavailability of free lutein and lutein ester, and explore the complex interplay between genetic variations, intestinal microbiota, and the dietary intervention in Chinese adults with long-term exposure to digital devices.MethodsThe Lutein, Zeaxanthin, and Omega-3 (LZO) clinical trial is a 24-week multicenter, randomized, double-blind, placebo-controlled trial of 600 participants recruited from research centers, universities, and communities. Individuals are eligible to participate if they are aged over 18 years and use digital devices for over 8 h daily in the last 2 years, and will be randomized to six arms. A total of three visits will be scheduled at baseline, 12 and 24 weeks. The primary outcome is the change in MPOD over the 24-week intervention. The secondary outcomes are changes in visual function (visual acuity, best-corrected visual acuity, contrast and glare sensitivity, critical flicker fusion, reaction time, visuognosis persistence, symptoms and signs of dry eye, retinal thickness, and optical quality), and changes in serum lutein and zeaxanthin concentrations, and erythrocyte membrane omega-3 fatty acids. Genetic variations will be determined using genome-wide genotyping at baseline. 16S rRNA gene sequencing will be utilized to assess microbiome compositional changes before and after intervention.DiscussionThe trial is anticipated to establish early interventions to prevent photochemical ocular damage and delay the onset of vision impairment in young adults with long-term repeated exposure to screen-based electronic devices, and provide valuable insights for the development of precision nutrition strategies for maintaining eye health.Clinical trial registrationwww.clinicaltrials.in.th, Identifier, TCTR20220904002.